Racura Oncology Ltd (ASX:RAC)

Racura Oncology Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Other Revenue	3.48	6.04	4.84	3.13	0.71	0.39
Revenue	3.48	6.04	4.84	3.13	0.71	0.39
Revenue Growth (YoY)	-46.10%	24.96%	54.29%	342.83%	82.71%	143.07%
Cost of Revenue	0.51	0.64	2.61	2.03	0.99	0.62
Gross Profit	2.97	5.41	2.22	1.11	-0.28	-0.23
Selling, General & Admin	3.52	3.28	3.79	3.04	4.33	3.34
Research & Development	6.9	5.9	10.98	7.6	5.83	2.2
Amortization of Goodwill & Intangibles	0.28	0.28	0.28	0.28	0.28	0.28
Other Operating Expenses	0.56	0.66	0.82	0.66	0.48	0.31
Operating Expenses	11.11	10.12	15.87	11.58	10.92	6.13
Operating Income	-8.14	-4.72	-13.65	-10.48	-11.2	-6.36
Interest & Investment Income	-	-	-	0.59	0.05	0.02
Other Non Operating Income (Expenses)	-0.11	-0.07	-0.17	-0.04	-0.05	-0.04
EBT Excluding Unusual Items	-8.25	-4.79	-13.82	-9.92	-11.2	-6.38
Other Unusual Items	-1.14	-	-	-	-	0.04
Pretax Income	-9.39	-4.79	-13.82	-9.92	-11.2	-6.34
Net Income	-9.39	-4.79	-13.82	-9.92	-11.2	-6.34
Net Income to Common	-9.39	-4.79	-13.82	-9.92	-11.2	-6.34
Shares Outstanding (Basic)	174	172	165	161	153	131
Shares Outstanding (Diluted)	174	172	165	161	153	131
Shares Change (YoY)	2.69%	4.81%	2.35%	4.83%	17.06%	22.86%
EPS (Basic)	-0.05	-0.03	-0.08	-0.06	-0.07	-0.05
EPS (Diluted)	-0.05	-0.03	-0.08	-0.06	-0.07	-0.05
Gross Margin	85.30%	89.49%	45.96%	35.35%	-39.91%	-60.07%
Operating Margin	-234.15%	-78.03%	-282.30%	-334.22%	-1582.76%	-1641.48%
Profit Margin	-270.04%	-79.22%	-285.76%	-316.60%	-1582.63%	-1636.70%
EBITDA	-7.86	-4.43	-13.37	-10.19	-10.92	-6.08
EBITDA Margin	-226.07%	-73.37%	-276.48%	-	-	-
D&A For EBITDA	0.28	0.28	0.28	0.28	0.28	0.28
EBIT	-8.14	-4.72	-13.65	-10.48	-11.2	-6.36
EBIT Margin	-234.15%	-78.03%	-282.30%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.